Evidence map›Paper›PMID 41899595›Full record

ArticleCancers2026

A Pathomics-Based Prognostic Model for Disease-Free Survival in Resected Gastric Cancer.

Liyun Zheng, Zhiying Jin, Fazong Wu, Shiman Zhu, Yeyu Zhang, Li Chen, Wanbin Chen, Chaoming Huang, Lingyi Zhu, Shiji Fang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Liyun ZhengZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Zhiying JinCancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Fazong WuZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Shiman ZhuZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Yeyu ZhangCancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Li ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Wanbin ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Chaoming HuangZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Lingyi ZhuZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Shiji FangZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Zijian ZhuZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Qi HuangZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Minjiang ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Zhongwei ZhaoZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Weiwen LiZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Shimiao ChengZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aims to develop and validate a prognostic risk model by integrating pathomics features with clinical variables to predict disease-free survival (DFS) in patients with gastric cancer (GC).

methodsPatients with GC who were pathologically diagnosed and subsequently treated with curative gastrectomy and D2 lymphadenectomy at the Fifth Affiliated Hospital of Wenzhou Medical University between January 2017 and April 2023 were retrospectively enrolled and assigned to a training cohort (

resultsA total of 16 pathomics features were selected, and the cut-off for the pathomics scores was set at 0.27. High-risk patients exhibited significantly worse DFS compared to low-risk patients in both the training cohort (HR = 4.57, 95% CI: 3.118-6.697,

conclusionsA clinic-pathomics model integrating pathomics features with clinical data provides a reliable tool for DFS prediction in patients with GC, which facilitates individualized DFS predictions and personalized treatment strategies.

Indexed as

clinical variablesdisease-free survivalgastric cancernomogrampathomicsprognostic model

Identifiers

PMID41899595
PMCPMC13025335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.